Major Insights from Global Glaucoma Therapeutics Market Presented in a New Research Offering Forecast 2017-2024

Published on : May 29, 2018

Albany, New York, May 29, 2018: Glaucoma is one of the most common eye diseases, striking 1 in 200 people below 50. The growing need to offer improved eye care and preserve the vision of the patients among healthcare providers has resulted in the development of superior therapeutic options for the treatment of glaucoma. To elaborate further, analyst has prepared a study titled “Glaucoma Therapeutics Market - Global Industry Analysis, Size, Share, Volume, Growth, Trends, and Forecast 2017-2024” which has been freshly broadcasted to the wide repository of Market Research Hub (MRH). This 160-page research publication is a combination of primary and secondary research, conducted for understanding and arriving at trends, used to forecast the expected revenue of the major glaucoma therapeutics market in the near future.

Research Overview and Forecast Insights

Glaucoma is an ocular disease which affects the optic nerve of the iris and progression of the same results into vision loss and blindness. In the initial section, the market overview section of the report explores the market dynamics such as drivers, restraints, and opportunities that currently have a strong impact on the glaucoma therapeutics market and how it will influence market growth in the coming years. In addition, the report focuses on analyzing past trends from 2012 to 2016 and forecasts future prospects from 2017 to 2024 of global glaucoma therapeutics market with a prime focus on some prime regions including Europe, North America, APEJ, Latin America, Japan and MEA.

According to the study evaluations, the market is anticipated to reach a value of US$7,691.4 million by the end of 2024, registering a healthy 3.44% CAGR between 2017 and 2024. In 2017, the global market valuation was worth US$6,071.0 million. The increasing number of cases of glaucoma and the rising demand for combination glaucoma drugs are some of the vital factors that are likely to encourage the growth of the global market in the next few years. Besides, the key players in the global market are focusing on solidification their drug pipeline of combination drugs is foretold to boost the growth of the global glaucoma therapeutics market throughout the forecast period.

Moreover, the study provides a comprehensive view of the market by dividing it into following segments: drug class, end-user, and geography. By drug class, it covers Alpha Agonist, Carbonic Anhydrase Inhibitor, Combined Medication, Beta Blockers, Prostaglandin Analogs and Cholinergic. Major end-user include ophthalmic clinic, ambulatory surgical centers and hospitals. In terms of geography, North America is expected to witness a strong growth in the next few years, owing to the rising geriatric population and the availability of several treatment options.

Later, the authors of the report have decoratively profiled the key players in order to provide a sound understanding of how the competitive landscape could shape in the near future. Presently, major companies functioning in the glaucoma therapeutics market are Merck & Co., Santen Pharmaceuticals, Allergan Inc., Valeant Pharmaceuticals Pfizer Inc., Novartis AG., and Aerie Pharmaceuticals.

Request a Sample with TOC in a PDF format :

About Market Research Hub

Market Research Hub (MRH) is a next-generation reseller of research reports and analysis. MRH’s expansive collection of market research reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps.

MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining industry trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients.

Research Assistance

For Enquiries, Call :

+1-800-998-4852US Toll Free

Email :

Back To Top